ASAM Practice Pearls

In this episode of ASAM Practice Pearls, Dr. Peter Selby and Dr. Emily Brunner explore behavioral addictions—including gaming, gambling, sex, and social media. They discuss how these behaviors impact the brain, how they present clinically, and how to recognize and treat them using evidence-based approaches. The episode emphasizes the importance of validating these conditions and offering appropriate care. 

----more----

Looking for this episode's transcript? Download it HERE

Peter Selby, MBBS, CCFP(AM), FCFP, FASAM 

Dr. Peter Selby is a Senior Scientist and Senior Medical Consultant at the Centre for Addiction and Mental Health (CAMH) and Vice-Chair, Research, and Giblon Professor in Family Medicine at the University of Toronto. His research focuses on innovative methods to understand and treat addictive behaviors and their comorbidities. He utilizes technology to scale and test health interventions, with his cohort of over 400,000 treated smokers in Ontario serving as an example. Dr. Selby has received over $100 million in grant funding from CIHR, NIH, and the Ministry of Health and has published more than 200 peer-reviewed articles. His most recent research program utilizes a Learning Health Systems approach to investigate how technology-equitable, collaborative care can enhance the delivery of evidence-based interventions to the patient while providing a more satisfying care experience for patients and providers across systems.

Emily Brunner, MD, DFASAM 

Dr. Emily Brunner is board-certified in family medicine and a distinguished fellow in addiction medicine. She has experience treating addiction in both inpatient and outpatient settings. She specializes in trauma-informed clinical treatment of substance use disorders with a comprehensive and compassionate approach. Dr. Brunner has been involved in leadership of the Minnesota Society of Addiction Medicine and is now on the national board of the American Society of Addiction. She is a passionate advocate for improving the care of patients with substance use disorder across the healthcare system, specifically in advocating for increased utilization of medications for opioid use disorder across all levels of care. Minnesota Magazine recognized her as a Top Doctor for Addiction Medicine in 2020 and 2021. She is the medical director of Gateway Recovery and Recovering Hope and does training on behalf of the Hazelden Betty Ford Foundation. 

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

In recognition of Sickle Cell Awareness Day (June 19), this episode of ASAM Practice Pearls features host Dr. Peter Selby and expert Dr. Andrew Smith as they explore the complex intersection of sickle cell disease (SCD), pain, and addiction. They discuss the challenges individuals with SCD face in accessing effective pain management, often compounded by stigma and opioid-related concerns. The episode provides insights into evidence-based treatments, the balance between pain relief and opioid dependence risks, and strategies for compassionate, patient-centered care.

----more----

Looking for this episode's transcript? Download it HERE

Peter Selby, MBBS, CCFP(AM), FCFP, FASAM 

Dr. Peter Selby is a Senior Scientist and Senior Medical Consultant at the Centre for Addiction and Mental Health (CAMH) and Vice-Chair, Research, and Giblon Professor in Family Medicine at the University of Toronto. His research focuses on innovative methods to understand and treat addictive behaviors and their comorbidities. He utilizes technology to scale and test health interventions, with his cohort of over 400,000 treated smokers in Ontario serving as an example. Dr. Selby has received over $100 million in grant funding from CIHR, NIH, and the Ministry of Health and has published more than 200 peer-reviewed articles. His most recent research program utilizes a Learning Health Systems approach to investigate how technology-equitable, collaborative care can enhance the delivery of evidence-based interventions to the patient while providing a more satisfying care experience for patients and providers across systems.

Andrew J. Smith, MDCM 

Dr. Andrew J. Smith is a Staff Physician, Pain and Addiction Medicine and Medical Lead of the Interprofessional Pain and Addiction Recovery Clinic at the Centre for Addiction and Mental Health in Toronto. He comes from McGill Medicine, University of Washington Neurology, and UCLA Medical Genetics, initially focusing on neurodevelopmental medicine. Frustrated by how many of his young patients with learning disabilities would fall into substance use problems despite early successes, he retooled in the field of addiction medicine. He became the first in Canada to do a combined clinical fellowship in pain and addictions at CAMH and Mount Sinai Hospital. He now leads an Interprofessional team dedicated to helping people with substance use disorders, severe mental health conditions, and chronic pain improve their pain, function, and quality of life. Dr. Smith is passionate about improving access to better care for patients with chronic pain and addiction, educating patients, families, and clinicians about pain and addiction, and reducing stigma. He is an executive and hub member of ECHO Ontario Chronic Pain — a telementoring resource for primary care clinicians to enhance their skills and confidence in managing more of their own patients who have complex pain and opioid issues.

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

In this episode of ASAM Practice Pearls, Dr. Stephen Taylor welcomes Dr. Marc Fishman for an insightful conversation on improving engagement and retention of youth in medication treatment for opioid use disorder (MOUD). They examine the unique challenges young people face and present developmentally informed strategies—including prevention, family involvement, and assertive outreach. The discussion highlights the importance of a medication-first approach and building partnerships with schools and communities to foster long-term recovery.

----more----

Looking for this episode's transcript? Download it HERE

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM

Dr. Stephen M. Taylor is ASAM's President and is board-certified in general psychiatry, child and adolescent psychiatry, addiction psychiatry, and addiction medicine. With over 30 years of practice experience, Dr. Taylor is dedicated to helping adolescents and adults overcome addiction and co-occurring psychiatric disorders. He has served as the Medical Director of the NBA and NBPA Player Assistance and Anti-Drug Program for 16 years and is the Chief Medical Officer of Pathway Healthcare, which operates multiple outpatient addiction and mental health treatment offices across six states. 

Marc Fishman, MD

Dr. Marc Fishman is a specialist in addiction psychiatry and addiction medicine. He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of SUD and co-occurring disorders in adolescents, young adults, and adults. He has been a principal investigator on numerous research studies in addiction and has published extensively in the field. His academic focus has been on medication treatment for OUD and other SUDs, treatment of opioid use disorder in youth, models of care, and treatment engagement strategies. Dr. Fishman served as a co-editor for past editions of ASAM’s Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He was a member of the Guideline Committee that developed the ASAM National Practice Guideline for the Treatment of OUD in 2015 and its update in 2020. He is the chair of the Adolescent SIG for ASAM. He is a Past President of the Maryland Society of Addiction Medicine and a current member of its Board.

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

This episode is part of a special four-part series spotlighting key sessions from ASAM’s 56th Annual Conference.

In this episode of ASAM Practice Pearls, Dr. Elizabeth Salisbury-Afshar is joined by Drs. Sarah Wakeman and Joshua Lee to review the most influential addiction medicine publications of 2024–2025. They discuss the criteria used to identify high-impact papers, highlight key findings, and explore how these insights can inform clinical practice and future research.

----more----

Looking for this episode's transcript? Download it HERE

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM

Dr. Elizabeth Salisbury-Afshar is a family medicine, preventive medicine/public health, and addiction medicine physician. She is an Associate Professor at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. She is a core faculty member for the Addiction Medicine Fellowship at the University of Wisconsin, and her clinical roles include addiction medicine consult service and serving as medical director of a low-barrier walk-in clinic serving people who use substances. She is also the Program Director of the Preventive Medicine Residency at UW-Madison and Medical Director of Harm Reduction Services at the Wisconsin Division of Public Health. Dr. Salisbury-Afshar's work focuses on expanding access to evidence-based addiction treatment and harm reduction services. She has over 14 years of experience practicing in medically underserved settings. Dr. Salisbury-Afshar lectures nationally on addiction medicine topics, including the treatment of opioid use disorder, harm reduction, the intersection of addiction and the criminal legal system, and public health approaches to reduce overdose mortality. Dr. Salisbury-Afshar is actively involved in ASAM, where she currently serves as the Vice Chair of the Medical Education Council, Course Director of the ASAM-All Rise treatment courts courses, a member of the ASAM Conference Planning Committee, and the Chair of Harm Reduction Special Interest Group.

Sarah E. Wakeman, MD, FASAM

Dr. Sarah Wakeman is the Medical Director for the Mass General Hospital Program for Substance Use & Addiction Services, Program Director of the Mass General Addiction Medicine fellowship, Senior Medical Director for Substance Use Disorder at Mass General Brigham, and an Associate Professor of Medicine at Harvard Medical School. She received her AB from Brown University and her MD from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine and board-certified in Addiction Medicine by the American Board of Preventive Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she serves on the American Society of Addiction Medicine Ethics Committee. Clinically, she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in general medical settings, low threshold treatment models, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

Joshua D. Lee, MD, MSc

Dr. Joshua Lee is a Professor in the Department of Population Health and Medicine/General Internal Medicine and Clinical Innovation at the NYU Grossman School of Medicine. He is Co-Director of the Section on Tobacco, Alcohol, and Drug Use and Program Director of the NYU Fellowship in Addiction Medicine. He is a clinician-researcher focused on addiction pharmacotherapies in primary care and criminal justice populations. 

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

This episode is part of a special four-part series spotlighting key sessions from ASAM’s 56th Annual Conference.

In this episode of ASAM Practice Pearls, Dr. Elizabeth Salisbury-Afshar is joined by Drs. Rachel Haroz, Bill Soares, and Ryan McCormack to discuss their session, Methadone Initiation for Opioid Use Disorder in the Emergency Department. The episode covers implementation strategies, regulatory considerations, and practical steps for introducing methadone as a treatment option in emergency care.

----more----

Looking for this episode's transcript? Download it HERE

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM

Dr. Elizabeth Salisbury-Afshar is a family medicine, preventive medicine/public health, and addiction medicine physician. She is an Associate Professor at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. She is a core faculty member for the Addiction Medicine Fellowship at the University of Wisconsin, and her clinical roles include addiction medicine consult service and serving as medical director of a low-barrier walk-in clinic serving people who use substances. She is also the Program Director of the Preventive Medicine Residency at UW-Madison and Medical Director of Harm Reduction Services at the Wisconsin Division of Public Health. Dr. Salisbury-Afshar's work focuses on expanding access to evidence-based addiction treatment and harm reduction services. She has over 14 years of experience practicing in medically underserved settings. Dr. Salisbury-Afshar lectures nationally on addiction medicine topics, including the treatment of opioid use disorder, harm reduction, the intersection of addiction and the criminal legal system, and public health approaches to reduce overdose mortality. Dr. Salisbury-Afshar is actively involved in ASAM, where she currently serves as the Vice Chair of the Medical Education Council, Course Director of the ASAM-All Rise treatment courts courses, a member of the ASAM Conference Planning Committee, and the Chair of Harm Reduction Special Interest Group.

Rachel Haroz, MD, FAACT

Dr. Rachel Haroz is an associate professor in the Department of Emergency Medicine at Cooper Medical School of Rowan University, the division head of toxicology and addiction medicine, and the center head of the Cooper Center for Healing. She is board-certified in Emergency Medicine, Medical Toxicology, and Addiction Medicine, obtaining her BA in Biology from Brandeis University, her MD from Tufts University, and completing a residency in Emergency Medicine and a fellowship in Medical Toxicology. She has spent the last 20 years working in inner city emergency departments, mostly in the Camden area. She helped build and now staffs the Cooper Center for Healing in Camden, New Jersey, an addiction medicine specialty Center dedicated to treating patients with substance use disorders. In 2016, she helped create and implement BupeFirst ED, an initiative to prescribe buprenorphine from the Emergency Department and bridge patients to treatment with various community partners, and in 2019, she helped launch BupeFirst EMS, an innovative program aimed at initiating buprenorphine via paramedics in the field. She is also heavily involved in education as well as various NJ state initiatives to better serve patients struggling with substance use disorders.

Bill E. Soares III, MD, MS

Dr. William (Bill) Soares is the Director of Harm Reduction Services in the Department of Emergency Medicine at Baystate Medical Center in Springfield, MA, and an Assistant Professor of Emergency Medicine at the University of Massachusetts Chan Medical School-Baystate. He is a practicing emergency and addiction medicine physician researcher who has spent the past 10 years focused on expanding medication treatments and harm reduction services for emergency department patients with opioid use disorder. In his role as Director of Harm Reduction Services, Dr. Soares oversees take-home Narcan, harm reduction safer supply distribution, buprenorphine, and methadone induction programs throughout the four emergency departments in the Baystate Health System. Dr. Soares’s research focuses on clinical decision-making in the emergency department. He has completed a NIDA K08 (1K08DA045933-01) project evaluating provider decisions to prescribe discharge opioid medications to patients presenting with an acutely painful condition. He currently has federal grants from NIDA, AHRQ, and SAMHSA focused on expanding medication treatment and harm reduction for people with substance use disorders. Recently, he led efforts to create a comprehensive inpatient addiction consultation service for the three Baystate community hospitals through a state-level opioid settlement fund grant administered through the Massachusetts Bureau of Substance Use and Addiction Services (BSAS).

Ryan McCormack, MD, MS

Dr. Ryan McCormack is an Associate Professor of Emergency Medicine at the NYU Grossman School of Medicine and practices clinically in the Bellevue Hospital Emergency Department (ED). He is an NIH-funded clinical investigator who has led several multicenter trials with a history of funding from the National Institute on Drug Abuse (NIDA) and its Clinical Trials Network (CTN) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). His research employs mixed quantitative and qualitative methods and implementation science approaches to translate efficacious behavioral treatments (e.g., motivational interviewing, case management) and pharmacotherapy (buprenorphine, methadone, naltrexone) for substance use disorders into ED settings with a particular focus on highly marginalized patient populations.

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

This episode is part of a special four-part series spotlighting key sessions from ASAM’s 56th Annual Conference.

In this episode of ASAM Practice Pearls, Dr. Stephen Taylor is joined by Drs. Jeanmarie Perrone and Alaina Steck to explore key insights from their session, Emerging Illicit Substances: What Clinicians Need to Know. The conversation covers emerging drugs of concern, clinical challenges, and practical strategies for clinicians navigating this rapidly evolving field.

----more----

Looking for this episode's transcript? Download it HERE

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM

Dr. Stephen M. Taylor is ASAM's President and is board-certified in general psychiatry, child and adolescent psychiatry, addiction psychiatry, and addiction medicine. With over 30 years of practice experience, Dr. Taylor is dedicated to helping adolescents and adults overcome addiction and co-occurring psychiatric disorders. He has served as the Medical Director of the NBA and NBPA Player Assistance and Anti-Drug Program for 16 years and is the Chief Medical Officer of Pathway Healthcare, which operates multiple outpatient addiction and mental health treatment offices across six states.

Jeanmarie Perrone, MD

Dr. Jeanmarie Perrone is a Professor in the Department of Emergency Medicine and the founding Director of the Center for Addiction Medicine and Policy at the University of Pennsylvania. Dr. Perrone leads programs for the treatment of Opioid and Alcohol Use Disorders in the emergency department (ED) and a virtual telehealth bridge clinic (CareConnect). Her work has been funded by city health departments and by NIDA, PCORI, CDC, and SAMHSA. She has advocated at the state and national levels and contributed to working groups to enhance low-barrier treatment access for substance use disorders. She has been recognized with awards for leadership, education and mentorship and her initiatives have been featured in the media including National Public Radio, the New York Times and USA Today.

Alaina Steck, MD

Dr. Alaina R. Steck is an Associate Professor in the Emory Department of Emergency Medicine. She completed her residency training in Emergency Medicine at Boston Medical Center in Boston, MA, and her fellowship in Medical Toxicology at the Emory / Centers for Disease Control and Prevention Combined Fellowship in Medical Toxicology, followed by board certification in Addiction Medicine. She currently serves as the Medical Director of the Grady Medication for Alcohol and Opioid Use Disorder Treatment clinic, the Addiction Medicine Clerkship Director, Assistant Medical Director at the Georgia Poison Center, and Pharmacology Thread Director at the Emory School of Medicine.

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

This episode is part of a special four-part series spotlighting key sessions from ASAM’s 56th Annual Conference.

In this episode of ASAM Practice Pearls, Dr. Elizabeth Salisbury-Afshar welcomes Dr. Itai Danovitch to explore highlights from his session, Hospitals as a Frontline for Addiction: Lessons from the START Study. They’ll discuss the pivotal role hospitals play in identifying and treating substance use disorders, drawing on insights and outcomes from the START (Substance Use Treatment and Recovery Team) Study. 

----more----

Looking for this episode's transcript? Download it HERE

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM

Dr. Elizabeth Salisbury-Afshar is a family medicine, preventive medicine/public health, and addiction medicine physician. She is an Associate Professor at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. She is a core faculty member for the Addiction Medicine Fellowship at the University of Wisconsin, and her clinical roles include addiction medicine consult service and serving as medical director of a low-barrier walk-in clinic serving people who use substances. She is also the Program Director of the Preventive Medicine Residency at UW-Madison and Medical Director of Harm Reduction Services at the Wisconsin Division of Public Health. Dr. Salisbury-Afshar's work focuses on expanding access to evidence-based addiction treatment and harm reduction services. She has over 14 years of experience practicing in medically underserved settings. Dr. Salisbury-Afshar lectures nationally on addiction medicine topics, including the treatment of opioid use disorder, harm reduction, the intersection of addiction and the criminal legal system, and public health approaches to reduce overdose mortality. Dr. Salisbury-Afshar is actively involved in ASAM, where she currently serves as the Vice Chair of the Medical Education Council, Course Director of the ASAM-All Rise treatment courts courses, a member of the ASAM Conference Planning Committee, and the Chair of Harm Reduction Special Interest Group.

Itai Danovitch, MD, MBA, DFAPA, DFASAM

Dr. Itai Danovitch is Professor and Chair of the Department of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center in Los Angeles. He earned his bachelor's degree from UC Berkeley and his medical doctorate from the UCLA School of Medicine. He completed a psychiatry residency at Columbia University, an addiction psychiatry fellowship at Cedars-Sinai Medical Center, and a Master of Business Administration at the UCLA Anderson School of Management. Dr. Danovitch’s clinical practice and research are focused on the treatment of substance use disorders and the integration of medical and mental health services. His current research is funded by the National Center for Advancing Translational Sciences (NCATS), the National Institute on Drug Abuse (NIDA), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). He is the author of over 100 articles and book chapters and co-editor of two books on substance use disorders. Dr. Danovitch served as a Governor-appointed state Commissioner to the California Mental Health Services Commission. He is a Distinguished Fellow of the American Society of Addiction Medicine, a Distinguished Fellow of the American Psychiatric Association, and past president of the California Society of Addiction Medicine.

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

In this episode of ASAM Practice Pearls, Dr. Stephen Taylor and Dr. Tessa Steel explore the management of alcohol withdrawal in ambulatory, hospital-based, and ED-initiated care settings. They discuss best practices, risk stratification, medication strategies, and emerging approaches to support effective withdrawal management.

----more----

Looking for this episode's transcript? Download it HERE

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM

Dr. Stephen M. Taylor is ASAM’s President-Elect and is board-certified in general psychiatry, child and adolescent psychiatry, addiction psychiatry, and addiction medicine. With over 30 years of practice experience, Dr. Taylor is dedicated to helping adolescents and adults overcome addiction and co-occurring psychiatric disorders. He has served as the Medical Director of the NBA and NBPA Player Assistance and Anti-Drug Program for 16 years and is the Chief Medical Officer of Pathway Healthcare, which operates multiple outpatient addiction and mental health treatment offices across six states.

Tessa Steel, MD, MPH

Dr. Tessa Steel is an Assistant Professor, physician-scientist, and Pulmonary Critical Care Medicine doctor at Harborview Medical Center, a county safety-net hospital operated by the University of Washington in Seattle. She is board-certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine. Her clinical and research interests include improving hospital-based treatments for alcohol withdrawal syndrome and using hospitalizations to help people with addiction launch their process of recovery. 

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

In this episode of ASAM Practice Pearls, Dr. Stephen Taylor and Dr. Melissa Weimer revisit the fundamentals of alcohol use disorder (AUD), discussing medications like acamprosate, disulfiram, naltrexone, topiramate, and others and how to support various treatment goals, whether that means reducing use or achieving abstinence. 

----more----

Looking for this episode's transcript? Download it HERE

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM

Dr. Stephen M. Taylor is ASAM’s President-Elect and is board-certified in general psychiatry, child and adolescent psychiatry, addiction psychiatry, and addiction medicine. With over 30 years of practice experience, Dr. Taylor is dedicated to helping adolescents and adults overcome addiction and co-occurring psychiatric disorders. He has served as the Medical Director of the NBA and NBPA Player Assistance and Anti-Drug Program for 16 years and is the Chief Medical Officer of Pathway Healthcare, which operates multiple outpatient addiction and mental health treatment offices across six states.

Melissa Weimer, DO, MCR, DFASAM

Dr. Melissa Weimer is board-certified in Internal Medicine and Addiction Medicine, focusing on substance use disorders in hospital settings.  She is an Associate Professor of Medicine at Yale School of Medicine and currently the Medical Director of the Yale Addiction Medicine Consult Service (YAMCS) at Yale New Haven Hospital. Dr. Weimer has worked on local, state, and national levels to enhance access to evidence-based treatments for substance use disorders.  As an educator, she teaches healthcare students and professionals about substance use disorders and serves as the Associate Program Director of the Yale Addiction Medicine Fellowship program. She is also the Medical Director/Lead Trainer for the SAMHSA-funded Providers Clinical Support System-Medications for Alcohol Use Disorder. 

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!

In this episode of ASAM Practice Pearls, Dr. Peter Selby and Dr. Emily Brunner explore The Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. They discuss key recommendations and best practices for tapering benzodiazepines safely and effectively. Additional topics include the risks and benefits of tapering, common withdrawal symptoms, strategies to support patients while minimizing new dependencies, and navigating patient resistance and fear.

----more----

Looking for this episode's transcript? Download it HERE

Peter Selby, MBBS, CCFP(AM), FCFP, FASAM 

Dr. Peter Selby is a Senior Scientist and Senior Medical Consultant at the Centre for Addiction and Mental Health (CAMH) and Vice-Chair, Research, and Giblon Professor in Family Medicine at the University of Toronto. His research focuses on innovative methods to understand and treat addictive behaviors and their comorbidities. He utilizes technology to scale and test health interventions, with his cohort of over 400,000 treated smokers in Ontario serving as an example. Dr. Selby has received over $100 million in grant funding from CIHR, NIH, and the Ministry of Health and has published more than 200 peer-reviewed articles. His most recent research program utilizes a Learning Health Systems approach to investigate how technology-equitable, collaborative care can enhance the delivery of evidence-based interventions to the patient while providing a more satisfying care experience for patients and providers across systems.

Emily Brunner, MD, DFASAM 

Dr. Emily Brunner is board-certified in family medicine and a distinguished fellow in addiction medicine. She has experience treating addiction in both inpatient and outpatient settings. She specializes in trauma-informed clinical treatment of substance use disorders with a comprehensive and compassionate approach. Dr. Brunner has been involved in leadership of the Minnesota Society of Addiction Medicine and is now on the national board of the American Society of Addiction. She is a passionate advocate for improving the care of patients with substance use disorder across the healthcare system, specifically in advocating for increased utilization of medications for opioid use disorder across all levels of care. Minnesota Magazine recognized her as a Top Doctor for Addiction Medicine in 2020 and 2021. She is the medical director of Gateway Recovery and Recovering Hope and does training on behalf of the Hazelden Betty Ford Foundation. 

Share your thoughts using #ASAMPracticePearls — we’d love to hear from you!